|
|
||||||||


*
Department of Immunopathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; and
Department of Dermatology, University of Tsukuba, School of Medicine, Tsukuba, Japan
| Abstract |
|---|
|
|
|---|
5% of steroid-resistant mature
CD4+8- thymocytes in normal naive mice,
produces various autoimmune diseases in syngeneic athymic nude mice.
These CD25+4+8- thymocytes are
nonproliferative (anergic) to TCR stimulation in vitro, but potently
suppress the proliferation of other CD4+8- or
CD4-8+ thymocytes; breakage of their anergic
state in vitro by high doses of IL-2 or anti-CD28 Ab simultaneously
abrogates their suppressive activity; and transfer of such
suppression-abrogated thymocyte suspensions produces autoimmune disease
in nude mice. These immunoregulatory
CD25+4+8- thymocytes/T cells are
functionally distinct from activated CD25+4+ T
cells derived from CD25-4+ thymocytes/T cells
in that the latter scarcely exhibits suppressive activity in vitro,
although both CD25+4+ populations express a
similar profile of cell surface markers. Furthermore, the
CD25+4+8- thymocytes appear to
acquire their anergic and suppressive property through the thymic
selection process, since TCR transgenic mice develop similar
anergic/suppressive CD25+4+8-
thymocytes and CD25+4+ T cells that
predominantly express TCRs utilizing endogenous
-chains, but
RAG-2-deficient TCR transgenic mice do not. These results taken
together indicate that anergic/suppressive
CD25+4+8- thymocytes and
peripheral T cells in normal naive mice may constitute a common T cell
lineage functionally and developmentally distinct from other T cells,
and that production of this unique immunoregulatory T cell population
can be another key function of the thymus in maintaining immunologic
self-tolerance. | Introduction |
|---|
|
|
|---|
We have shown previously that elimination of CD25+ peripheral T cells, which constitute 510% of peripheral CD4+ T cells and less than 1% of CD8+ T cells in normal naive mice, produces various autoimmune diseases in otherwise normal mice; and the reconstitution of the eliminated population prevents the autoimmune development (13, 14). These naturally present immunoregulatory CD25+4+ T cells are unique in that 1) they are anergic to TCR stimulation in vitro (24), if one defines anergy as a reversible antiproliferative state (25); 2) upon TCR stimulation, however, they potently suppress the activation/proliferation of other CD4+ T cells and CD8+ T cells in an Ag-nonspecific manner (24); furthermore, 3) in contrast to other regulatory T cells exerting cytokine-mediated control on autoimmune T cells (26, 27, 28, 29, 30), the CD25+4+ T cells suppressively control other T cells on the surface of APC through a cognate cellular interaction (24, 31). It remains to be determined, however, where and how the CD25+4+ T cells acquire the anergic, suppressive, and autoimmune-preventive property.
In this study, we attempt to determine the origin of these naturally anergic and suppressive CD25+4+ T cells, and to examine their role in maintaining immunologic self-tolerance. We demonstrate that the normal thymus is continuously generating and releasing not only pathogenic self-reactive T cells, but also the CD25+4+ anergic/suppressive T cells, that the latter are rendered anergic and suppressive through the thymic selection process, and that physical elimination of such immunoregulatory CD25+4+8- thymocytes or functional breakage of their anergic/suppressive state can elicit autoimmune disease in otherwise normal mice. Our results indicate that, besides clonal deletion and clonal anergy, production of this naturally anergic and suppressive CD25+4+ T cell population is another key function of the thymus in maintaining immunologic self-tolerance.
| Materials and Methods |
|---|
|
|
|---|
Eight-week-old BALB/c or BALB/c nu/+ mice and six-week-old BALB/c nude (nu/nu) mice were purchased from SLC (Shizuoka, Japan). BALB/c-Thy-1a congenic mice were established in our laboratory (14). DO11.10 transgenic mice were the gift of Dr. D. Y. Loh, Roche Japan (Kamakura, Japan) (32). DO11.10-RAG-2 knockout mice were provided by Drs. K. Iwabuchi (Hokkaido University, Sapporo, Japan) and O. Kanagawa (Washington University, St. Louis, MO) (33). All of these mice were maintained in our animal facility and cared for in accordance with the institutional guidelines for animal welfare.
Preparation of lymphocytes
Thymocyte suspensions (5 x 107), or spleen and lymph node cell suspensions (5 x 107) were incubated in 12 x 75-mm glass tubes (Corning, Corning, NY) with 100 µl of 1/10-diluted ascites of anti-CD25 (7D4, rat IgM) (34) or anti-CD8a.2 (mouse IgG2a) (35) for 45 min on ice, washed once with HBSS (Life Technologies, Gaithersburg, MD), incubated with 1 ml of nontoxic rabbit serum (as C source) (Life Technologies) 1/5 diluted with Medium 199 (Life Technologies) for 30 min in a 37°C water bath with occasional vigorous shakings, with 100 µg of DNase I (Sigma, St. Louis, MO) added for the last 5 min of the incubation, washed twice with HBSS, and then i.v. injected into 68-wk-old female nu/nu mice, as previously described (13).
Serologic analysis
For flow-cytometric analysis, 1 x 106 cells were incubated with FITC-labeled or biotinylated mAbs, with PE-streptavidin (BioMeda, Foster City, CA) as the secondary reagent for biotinylated Abs, and analyzed by a flow cytometer (Epics-XL; Coulter, Miami, FL) with exclusion of dead cells by propidium iodide staining. R-Phycoerythrin (RPE)-Cy5-conjugated streptavidin (Dako, Glostrup, Denmark) was used as the secondary reagent for biotinylated Abs in three-color analyses. FITC-labeled or biotinylated anti-CD25 (7D4) (34), and biotinylated Abs for CD4 (H129.19), CD54 (ICAM-1) (3E2) (36), CD5 (53-7.3) (37), CD8 (53-6.7) (37), CD11a/CD18 (LFA-1) (2D7) (38), CD24 (heat-stable Ag) (M1/69), CD44 (IM7) (39), CD45RB (16A) (40), CD62L (L-selectin) (Mel-14) (41), CD69 (H1.2F3) (42), CD90.2 (Thy-1.2) (30-H12), CD2 (RM2.5), or TCR Vß8.1, 8.2, 8.3 (F23.1) (43) were purchased from PharMingen (San Diego, CA). Anti-CD122 (IL-2R ß-chain) (TM-ß1) (44) and anti-DO11.10 clonotypic Ab (KJ1-26) (45) were the gifts of Dr. T. Tanaka (Osaka University, Osaka, Japan) and Dr. O. Kanagawa (Washington University, St. Louis, MO), respectively.
Cell sorting
Spleen and lymph node suspensions or thymocyte suspensions
prepared from 8-wk-old BALB/c mice were stained with FITC-conjugated
anti-CD25 (7D4) (PharMingen) and PE-conjugated anti-CD4
(H129.19) (PharMingen), and sorted by a FACS (Epics-Elite; Coulter), as
previously described (14). Purity of the CD25+ and
CD25-CD4+ populations was >90 and
99%,
respectively.
In vitro proliferation assay
Along with RBC-lysed and mitomycin C-treated BALB/c spleen cells
(5
10 x 104) as APCs, thymocytes or lymph
node/spleen cells (2
2.5 x 104), sorted as
described above, were cultured for 3 days in 96-well round-bottom
plates (Costar, Cambridge, MA) in RPMI 1640 medium supplemented with
10% FCS (Life Technologies), penicillin (100 U/ml), streptomycin (100
µg/ml), and 50 µM 2-ME (24). Anti-CD3 Ab (145-2C11) (46) (Cedarlane
Laboratories, Hornby, Ontario, Canada) at a final concentration of 10
µg/ml, Con A at 1 µg/ml, or OVA peptides (residue 323339) (27) at
0.3 µM were added to the culture for stimulation (24). Incorporation
of [3H]thymidine ([3H]TdR) (1 µCi/well)
by proliferating lymphocytes during the last 6 h of the culture
was measured. In expressing the degree of suppression exerted by
CD25+4+8- thymocytes on
CD25-4+8- thymocytes, percentage
of suppression was defined as 100 x [(cpm of
CD25-4+8- thymocytes - cpm
of the mixed population)/cpm of
CD25-4+8- thymocytes].
Murine rIL-2 (3.89 x 106 U/mg) was a gift of Shionogi (Osaka, Japan). Anti-CD28 mAb (37.51) (47) was purchased from PharMingen. To prepare Con A blasts for in vivo transfer, thymocytes (5 x 106/ml) were cultured with 5 µg/ml Con A for 3 days.
Steroid treatment of mice
Eight-week-old BALB/c mice were i.p. injected with 2.5 mg of hydrocortisone acetate (Sigma) 2 days before use.
Intrathymic injection
A 25 µl volume of CD4-CD8- thymocytes (1 x 105) purified by FACS from BALB/c thymocyte suspensions stained with PE anti-CD4 Ab and FITC anti-CD8 Ab, as described above, was injected into each lobe of the thymus exposed by incision of the sternum. The thymic region of the recipient BALB/c-Thy-1a mice was irradiated at 6 Gy before injection by covering extremities with lead plates (15).
Histology and serology
Stomachs and other organs were fixed with 10% Formalin and processed for hematoxylin and eosin staining. Serum titers of autoantibodies specific for the gastric parietal cells were assessed by ELISA (48). Gastritis was graded 02+, depending on macroscopic and histologic severity: 0 = the gastric mucosa was histologically intact; 1+ = gastritis with histologically evident destruction of parietal cells and cellular infiltration of the gastric mucosa; 2+ = severe destruction of the gastric mucosa accompanying the formation of giant rugae due to compensatory hyperplasia of mucus-secreting cells (8, 13, 14). Thyroiditis and oophoritis were histologically graded, as previously described (48). Adrenalitis, insulitis, and sialoadenitis were assessed as histologically positive when destruction of adrenocorical cells, Langerhans islet cells, or acinar cells in the submandibular glands, respectively, was histologically evident with infiltration of inflammatory cells to these tissues (48, 49). Glomerulonephritis was assessed as histologically positive when more than 50% of the renal glomeruli on a section were damaged with deposition of PAS (periodic acid-Schiff) staining-positive material (see 22).
| Results |
|---|
|
|
|---|
Fig. 1
A shows that a
significant percentage (5.4 ± 1.9%, n = 32) of
CD4+8- thymocytes and less than 0.3% of
CD4-8+ thymocytes in normal adult BALB/c mice
expressed the CD25 molecule at equivalent levels as peripheral
CD25+4+ T cells (Fig. 1
B) and at
lesser levels compared with the high level expression in the
CD4-8- population (50, 51). Immunohistologic
examination revealed that these
CD25+4+8- thymocytes located in
the thymic medulla, in contrast to
CD25high4-8- thymocytes in the
subcortical area (data not shown).
|
20%) were Qa-2+, compared with <1% of
Qa-2+ cells among
CD25-4+8- thymocytes (data not
shown). Taken together, the phenotype of
CD25+CD4+8- thymocytes (e.g.,
their CD5high, CD11a/CD18high,
CD44high, CD45RBlow, CD62Lhigh, and
CD54high expression) suggests that they may be in a more
mature, activated, or primed state than
CD25-4+8- thymocytes (54, 55, 56);
CD69 and/or Qa-2 expression on some
CD25+4+8- thymocytes, together
with their no CD24 expression (data not shown), suggests that they may
have been recently selected (57, 58, 59, 60); and CD5high,
CD45RBlow, and CD62Lhigh phenotype of
CD25+4+8- thymocytes is
similar to the phenotype of immunoregulatory T cell populations
previously reported by us and others (8, 9, 10, 12, 13, 14, 15, 16, 52, 53).
These expression patterns of cell surface molecules were similar
between CD25+4+8- thymocytes and
CD25+4+ T cells in the lymph nodes (Fig. 1
, B and C). Furthermore, both
CD25+4+8- thymocytes and
CD25+4+ T cells did not express NK1.1 Ag in
C57BL/6 mice (data not shown), indicating that they are different from
NKT cells (61, 62).
Induction of autoimmune disease by eliminating CD25+4+8- thymocytes
To determine whether
CD25+4+8- thymocytes suppressively
control pathogenic self-reactive thymocytes/T cells, we removed
CD25+ thymocytes from thymocyte suspensions prepared from
normal BALB/c nu/+ mice by in vitro treatment with
anti-CD25 mAb and C, and then transferred the remaining cells
(5 x 107) to BALB/c athymic nu/nu mice
(Table I
, Fig. 2
). In 3 mo, the transfer produced
histologically and serologically evident autoimmune diseases at higher
incidences and in a wider spectrum of organs (such as the gastric
mucosa, thyroid glands, salivary glands, adrenal glands, and ovaries
(see Refs. 8 and 22 for histology)) than the transfer of nondepleted
thymocyte suspensions, which produced only autoimmune gastritis in some
nude mice, but no other autoimmune diseases. Glomerulonephritis that
developed in some of the CD25- thymocyte-transferred nude
mice was due to the deposition of immune complexes in the renal
glomeruli, as previously described (13, 22). Hemolytic anemia or
inflammatory bowel disease as reported in CD25 gene-knockout mice was
not observed in the thymocyte-transferred nude mice (63).
|
|
Thus, the normal thymus contains both CD25-4+ pathogenic self-reactive T cells and CD25+4+ autoimmune-preventive T cells in the compartment of mature thymocytes. Furthermore, when pathogenic self-reactive T cells are released from the thymus, they can be controlled by CD25+4+ T cells already present in the periphery.
Origin of CD25+4+8- thymocytes
To determine the origin of the
CD25+4+8- thymocytes (i.e.,
whether they have differentiated in the thymus from immature thymocytes
or migrated from the periphery as activated T cells (64, 65)), immature
CD4-8- thymocytes prepared from BALB/c mice,
in which thymocytes express Thy-1.2 (CD90.2) Ag, were directly injected
into the thymus of BALB/c-Thy-1a congenic mice,
which express Thy-1.1 (CD90.1) Ag (Fig. 3
A). Staining of the recipient
thymus 1 wk later with anti-Thy-1.2 Ab revealed that the
CD25+4+8- population indeed
contained a significant number of donor-derived Thy-1.2+
cells. This indicates that the inoculated
CD4-8- thymocytes gave rise to
CD25+CD4+8- thymocytes.
CD25+4+8- thymocytes also
developed in vitro from CD4-8- thymocytes in
an organ culture of fetal thymus (data not shown). Furthermore, they
were already present in the thymus of newborn mice before 3 days of age
when CD25+4+ T cells could be first detected in
the periphery (14); for example, a significant proportion (0.9 ±
0.6%, n = 6) of CD4+ thymocytes (including
CD4+8+ and CD4+8-
thymocytes) was CD25+ in 2-day-old mice, whereas no
CD25+ T cells were detected in their spleens (Fig. 3
B). These results taken together indicate that most, if not
all, CD25+4+8- thymocytes are
generated in the thymus rather than having migrated from the periphery.
|
CD25+4+8- thymocytes purified
by FACS (as shown in Fig. 1
B) from normal adult BALB/c mice
exhibited virtually no response to in vitro stimulation with
anti-CD3 Ab or Con A (Fig. 4
,
A and B), whereas the purified
CD25-4+8- thymocytes showed
significantly higher responses than the unseparated
CD4+8- thymocytes. Furthermore,
CD25+4+8- thymocytes suppressed
the responses of CD25-4+8-
thymocytes (and CD4-8+ thymocytes) in a
dose-dependent fashion when the two populations were mixed in various
ratios and stimulated with anti-CD3 Ab (e.g., percentage of
suppression (see Materials and Methods) was >95% in every
experiment at a 1:1 ratio of cell mixing).
CD25+4+8- thymocytes also
suppressed the responses of CD25-4+ peripheral
T cells; likewise, CD25+4+ peripheral T cells
suppressed the responses of
CD25-4+8- thymocytes as well as
CD25-4+ peripheral T cells (Fig. 4
B). These results taken together indicate that the
CD25+4+8- population in the thymus
of normal naive mice is naturally unresponsive to Ag stimulation, but,
upon stimulation, suppresses the activation/proliferation of other
thymocytes/T cells; and it is functionally similar to the peripheral
CD25+4+ T cell population, which is also
anergic and suppressive.
|
Given that Ag stimulation together with exogenous IL-2 or
anti-CD28 Ab breaks T cell unresponsiveness in vitro (47, 66, 67),
we examined the effect of IL-2 or anti-CD28 Ab on the
unresponsiveness of CD25+4+ thymocytes and
their suppressive activity (Fig. 5
,
A and B). Stimulation of
CD25+4+8- thymocytes with
anti-CD3 Ab in the presence of exogenously added rIL-2 (100 U/ml
concentration) or anti-CD28 Ab (10 µg/ml) not only elicited their
proliferation, but also abrogated their suppressive activity.
|
The in vitro analyses described above suggest the possibility that
autoimmune disease may develop in normal mice if the abrogation of the
anergic/suppressive state of
CD25+4+8- thymocytes leads to the
activation of self-reactive T cells from CD25- dormant
states. To test this, thymocyte suspensions from euthymic BALB/c
nu/+ mice were stimulated with Con A and exogenous rIL-2 (at
50 U/ml), or Con A alone, for 3 days and then transferred to BALB/c
athymic nude mice, which were histologically and serologically examined
3 mo later (13). Transfer of Con A/rIL-2-stimulated thymocyte
suspensions (1 x 107) produced significantly higher
incidences of histologically evident autoimmune gastritis
(p = 0.036 by Fishers exact probability test)
and higher titers of anti-parietal cell autoantibodies than the
transfer of the same number of thymocytes stimulated with Con A alone
(Fig. 6
). The former also elicited other
autoimmune diseases, such as oophoritis and thyroiditis, in
20% of mice, whereas the latter did not. Thus, breakage of the anergic
and suppressive state of CD25+4+8-
thymocytes can elicit autoimmune diseases similar to those produced by
direct removal of CD25+4+8-
thymocytes or T cells.
|
Our previous reports showed that CD25-4+
T cells could differentiate into CD25+ T cells in vivo (13, 14). This raises the question as to whether such
CD25-4+ T cell-derived
CD25+4+ T cells (including activated autoimmune
effector T cells) can be phenotypically and functionally discriminated
from the anergic/suppressive CD25+4+ T cells
present in naive mice. To examine this, we analyzed the cell surface
phenotype, as well as the in vitro responsiveness to TCR stimulation,
of CD25+ or CD25-4+ lymph node T
cells prepared from nude mice that developed autoimmune disease after
transfer of CD25- T cells (as shown in Table I
and 13) (Fig. 7
). Compared with
CD25+4+ lymph node T cells in normal naive
mice, those in the CD25- cell-transferred nude mice, in
which CD25+ cells constituted 17.1 ± 5.2%
(n = 4) of lymph node CD4+ T cells (see
also legend to Fig. 7
D), were lower in CD62L and CD45RB
expression, and higher in CD69 expression, indicating that they were in
activated and/or primed states (Fig. 7
A). In the paragastric
lymph nodes of gastritis-bearing mice, CD25+4+
T cells expressed CD62L and CD45RB at much lower levels and CD69 at
much higher levels than those in other lymph nodes, indicating that
they were more primed and activated (Fig. 7
B). Transfer of
CD25- thymocytes (as shown in Table I
) also led to the
development of CD25+ or CD25-4+ T
cells with similar expression patterns of cell surface molecules (data
not shown).
|
These results taken together indicate that although CD25-4+ T cells can give rise to activated CD25+4+ T cells (including autoimmune effector T cells), they may be unable to generate CD25+4+ T cells with significant suppressive activity.
Development of anergic/suppressive CD25+4+8- thymocytes/T cell in TCR transgenic mice, but not in those on RAG-2-deficient background
CD25+4+8- thymocytes and T
cells developed in TCR transgenic mice as in nontransgenic mice.
DO11.10 transgenic mice expressing transgenic TCRs specific for an OVA
peptide, for example, harbored
CD25+4+8- thymocytes and
CD25+4+ peripheral T cells in a similar
proportion of CD4+8- thymocytes or
CD4+ T cells (3.5 ± 1.2% and 4.2 ± 0.9%
(n = 5), respectively) (Fig. 8
A). In contrast, DO11.10
transgenic mice on RAG-2 gene-deficient background developed few
CD25+4+8- thymocytes/T cells
(<0.1% of CD4+8- thymocytes or
CD4+ T cells). Furthermore, the
CD25+4+8- population in the thymus
and periphery of DO11.10 mice contained a 2
3-fold lower percentage
of KJ1-16+ thymocytes/T cells (hence higher percentage of
thymocytes/T cells expressing endogenous
-chains) compared with the
thymic or peripheral CD25-4+8-
population (18.3 ± 1.5% vs 72.7 ± 7.6% for thymocytes
(n = 3), 34.0 ± 8.7% vs 69.7 ± 8.9% for
lymph node cells (n = 4)); in contrast, each population
in the thymus and periphery contained a comparable percentage of
Vß8-expressing cells, the majority of which were expressing
transgenic Vß chains (27) (Fig. 8
A).
|
Thus, high percentages of T cells expressing endogenous TCR
-chains
in the thymic or peripheral CD25+4+ population,
together with the paucity of the population in RAG-2-deficient TCR
transgenic mice, indicate that rearrangement of the endogenous TCR
-chain genes and consequent expression of TCRs composed of
endogenous
-chains and transgenic ß-chains may be required for the
generation of anergic and suppressive
CD25+4+8- thymocytes/T
cells in TCR transgenic mice.
| Discussion |
|---|
|
|
|---|
|
-chains is required for their development in TCR
transgenic mice, as illustrated by the finding that RAG-2 deficiency
abrogated their development (Fig. 8
/ß-chains and the other of an endogenous
-chain and
the transgenic ß-chain; and, while the former recognize the OVA
peptide (and may transmit signals required for the cell to exert
suppression), the latter might be responsible for rendering
CD25+4+8- thymocytes anergic and
suppressive through the thymic selection process presumably by
interacting with self peptide/class II MHC (49, 69, 70, and see below).
These findings in OVA-TCR transgenic mice can be generalized to other
TCR transgenic mice. For example, in the mice expressing self-reactive
transgenic TCRs specific for the myelin basic protein or a pancreatic
islet cell Ag, the development of autoimmune diseases (such as
experimental allergic encephalomyelitis and insulin-dependent diabetes
mellitus, respectively) was enhanced significantly by making the
transgenic mice RAG-2 deficient or TCR C
deficient (hence,
endogenous TCR
-chain deficient) (71, 72). To further elucidate how
the anergic/suppressive CD25+4+8-
thymocytes are generated in the thymus of normal or TCR transgenic
mice, it is necessary to determine their Ag specificities or the
ligands selecting them. We postulate that the
CD25+4+8- thymocytes may be
reactive with self peptides/class II MHC complexes (57, 73) or class II
MHC itself (74) expressed in the thymus and rendered anergic (hence,
harmless) because the avidities of their TCRs for self peptides/class
II MHC might be rather high (but not so high as to be deleted) (Fig. 9
The CD25 molecule is expressed on activated T cells (34, 75). This
poses a question as to whether activated
CD25+4+ T cells derived from
CD25-4+ T cells can also acquire the
suppressive activity. In our study, the CD25+4+
T cells that had differentiated in nude mice from the inoculated
CD25-4+ T cells exhibited the cell surface
phenotype generally shared by activated, primed, or memory
CD4+ T cells and similar to the phenotype of
CD25+4+ T cells in normal naive mice (Fig. 7
, A and B, vs Fig. 1
C). They, however,
scarcely exhibited suppressive activity (Fig. 7
, C and
D). Although these CD25- cell-derived
CD25+4+ T cells were hyporesponsive to TCR
stimulation (Fig. 7
C), this could be attributed to the
refractoriness of chronically stimulated T cells (including autoimmune
effector T cells) to further TCR stimulation, as
CD25-4+8- thymocytes stimulated
in vitro were hyporesponsive to further stimulation (Fig. 5
C). Indeed, CD25+4+ T cells
prepared in vitro by activating CD25- T cells from normal
BALB/c mice did not exhibit suppressive activity either on the
proliferation of other T cells in vitro (Fig. 5
C) or on the
development of autoimmune disease in vivo when cotransferred to nude
mice with CD25- T cells (Y. Kuniyasu et al., manuscript in
preparation). Furthermore, the anergic/suppressive state of
CD25+4+8- thymocytes or
CD25+4+ peripheral T cells in normal naive mice
appears to be their basal default condition, since the
CD25+4+8- thymocytes/T cells
broken of their anergic/suppressive state by TCR stimulation along with
anti-CD28 Ab or a high dose of IL-2 reverted to the original
anergic/suppressive state upon removal of anti-CD28 Ab or IL-2 from
the culture milieu (Fig. 5
C and 24). Taken together,
these results indicate that, once the
CD25+CD4+8- thymocytes acquire the
suppressive activity in the thymus, they may stably maintain the
activity, and that other T cells could hardly acquire it upon
activation in the periphery (Fig. 9
). Our findings, which were mainly
obtained from in vitro proliferation assay, would not, however, exclude
the possibility that CD25- cell-derived CD25+
activated T cells might somehow suppressively influence functions of
other T cells in vivo through the cytokine network (13, 26, 27, 28, 29, 30). Other
T cells with activated phenotype, for example NKT cells, may also play
a regulatory role in self-tolerance by secreting immunoregulatory
cytokines, although both CD25+4+8-
thymocytes and CD25+4+ peripheral T cells do
not express NK1.1 Ag, indicating that they are different from NKT cells
(61, 62).
Together with this possible inability of
CD25-4+ T cells to acquire the
anergic/suppressive property upon activation, the following findings
suggest that the anergic/suppressive
CD25+4+8- T cells in the thymus
and periphery of normal naive mice may have developmental continuity as
a common T cell lineage and constitute a T cell subpopulation
functionally distinct from other T cells or thymocytes. First, both the
thymic and the peripheral CD25+4+ T cells are
functionally similar in their in vivo autoimmune prevention, in vitro
suppression, and unresponsiveness to TCR stimulation. Second, they are
phenotypically similar in the expression profile of various cell
surface molecules (Fig. 1
, B and C), especially
in high CD62L expression, which contrasts with low CD62L expression on
autoimmune effector T cells (Fig. 7
) or usual activated or memory T
cells (40, 54, 55, 56). The finding that
CD25+4+8- thymocytes/T cells are
CD5high, CD45RBlow, and partially
CD62Lhigh also correlates with the findings made by us and
others that autoimmune-suppressive CD4+ thymocytes/T cells
are CD5high, CD45RBlow, and
CD62Lhigh (8, 9, 10, 12, 13, 14, 15, 16, 52, 53), although it remains to
be determined whether the thymocyte/T cell population with the
anergic/suppressive property can be further reduced to a smaller
population, for example, the CD62Lhigh or
CD62Llow population included in the
CD25+4+8- population (Fig. 1
, B and C). Third, both
CD25+4+8- thymocytes and
CD25+4+ peripheral T cells are absent in
RAG-2-deficient TCR transgenic mice; and, in TCR transgenic mice, both
are constituted of high proportions of thymocytes/T cells expressing
endogenous TCR
-chains (Fig. 8
and see discussion above).
Furthermore, both were shown to be characteristically resistant to a
superantigen-induced clonal deletion (76, 77).
Given the thymic production of the anergic/suppressive
CD25+4+ thymocytes, their possible lineage
continuity to the peripheral CD25+4+ T cells,
and possible inability of other T cells to acquire the
anergic/suppressive property (see above), abrogation of their
peripheral migration from the beginning of their ontogeny may well lead
to their paucity in the periphery and, as a consequence, to the
development of autoimmune disease. In the previous report (14), we
showed that CD25+4+ T cells begin to appear in
the periphery at about day 3 after birth in normal mice; they are
substantially reduced by thymectomy at about day 3; such neonatal
thymectomy elicited autoimmune diseases similar to those produced in
the present experiments; and the inoculation of
CD25+4+ T cells from normal mice prevented the
autoimmune development. These findings taken together indicate that the
neonatal thymectomy may be able to selectively reduce the
anergic/suppressive CD25+4+ T cells in the
periphery, leading to activation of self-reactive T cells that have
migrated to the periphery before the thymectomy (see Fig. 3
B), thus resulting in the development of autoimmune
diseases similar to those produced by direct removal of
CD25+4+ T cells from the periphery of adult
mice (Table I
and Refs. 13 and 14). Other ways of possibly manipulating
the neonatal development of the anergic/suppressive
CD25+4+ thymocytes/T cells or reducing them
from the periphery in adults can cause similar autoimmune diseases as
well (19, 48, 49, 78).
Our results also indicate that not only physical elimination of
CD25+4+8- thymocytes/T cells, as
discussed above, but also functional abrogation of their suppressive
activity may cause autoimmune disease. For example, a high dose of IL-2
locally produced by T cells responding to invading microbes or a high
level of CD80/CD86 expression on APCs might locally break the
anergic/suppressive state of
CD25+4+8- thymocytes/T cells and
allow pathogenic self-reactive T cells in the vicinity to be activated
(79). Furthermore, breakage of the anergic/suppressive state of
CD25+4+ T cells for a limited period may
suffice to elicit autoimmune disease, as illustrated by the development
of autoimmune disease in nude mice transferred with thymocytes treated
in vitro with Con A and IL-2 for 3 days (Fig. 6
). It is likely that a
sufficient number of CD4+ pathogenic self-reactive T cells
in the inocula have expanded and/or differentiated to autoimmune
effector T cells before the anergy/suppression-broken
CD25+4+ T cells revert to the anergic state and
reacquire the suppressive activity (Fig. 5
C).
In conclusion, the present results indicate that the thymus contributes to the maintenance of immunologic self-tolerance not only by clonally deleting or inactivating self-reactive T cells, but also by producing CD25+4+ immunoregulatory T cells that are anergic and suppressive. Thus, pathogenic self-reactive T cells having escaped thymic clonal deletion can be controlled in the periphery by this T cell-mediated regulatory mechanism. Autoimmune disease may develop in genetically susceptible individuals as a consequence of abnormality in the thymic production of these naturally anergic and suppressive CD25+4+8- T cells, their reduction in the periphery, or their dysfunction in controlling self-reactive T cells. Environmental agents or genetic abnormalities may cause autoimmune disease by affecting CD25+4+8- thymocytes/T cells (80).
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Shimon Sakaguchi, Department of Immunopathology, Tokyo Metropolitan Institute of Gerontology, Sakaecho 35-2, Itabashi-ku, Tokyo 173-0015, Japan. E-mail address: ![]()
Received for publication November 9, 1998. Accepted for publication February 12, 1999.
| References |
|---|
|
|
|---|
-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.[Abstract]
ß+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mice. J. Immunol. 161:2620.
/ß cells: new clues to their origin, specificity, and function. J. Exp. Med. 182:638.
/ß-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187:1047.
-chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521.[Medline]
chains on the surface of T cells in T cell receptor transgenic mice. J. Exp. Med. 178:1807.
chain, resistance to clonal deletion and IL-2 dependency. Int. Immunol. 10:371.This article has been cited by other articles:
![]() |
X. Chen, L. Fang, S. Song, T. B. Guo, A. Liu, and J. Z. Zhang Thymic Regulation of Autoimmune Disease by Accelerated Differentiation of Foxp3+ Regulatory T Cells through IL-7 Signaling Pathway J. Immunol., November 15, 2009; 183(10): 6135 - 6144. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. O'Mahony, H. van der Kleij, J. Bienenstock, F. Shanahan, and L. O'Mahony Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2009; 297(4): R1118 - R1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-p. Zeng, C. Chang, and J.-j. Lai Immune Suppressive Activity and Lack of T Helper Differentiation Are Differentially Regulated in Natural Regulatory T Cells J. Immunol., September 15, 2009; 183(6): 3583 - 3590. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Windish, P. L. Lin, J. T. Mattila, A. M. Green, E. O. Onuoha, L. P. Kane, and J. L. Flynn Aberrant TGF-{beta} signaling reduces T regulatory cells in ICAM-1-deficient mice, increasing the inflammatory response to Mycobacterium tuberculosis J. Leukoc. Biol., September 1, 2009; 86(3): 713 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Guerin, J. R. Prins, and S. A. Robertson Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum. Reprod. Update, September 1, 2009; 15(5): 517 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Joetham, K. Takeda, M. Okamoto, C. Taube, H. Matsuda, A. Dakhama, and E. W. Gelfand Antigen Specificity Is not Required for Modulation of Lung Allergic Responses by Naturally Occurring Regulatory T Cells J. Immunol., August 1, 2009; 183(3): 1821 - 1827. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen, R. Das, R. Komorowski, A. Beres, M. J. Hessner, M. Mihara, and W. R. Drobyski Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease Blood, July 23, 2009; 114(4): 891 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Gregerson, N. D. Heuss, U. Lehmann, and S. W. McPherson Peripheral Induction of Tolerance by Retinal Antigen Expression J. Immunol., July 15, 2009; 183(2): 814 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Satpute, J. M. Park, H. R. Jang, P. Agreda, M. Liu, M. T. Gandolfo, L. Racusen, and H. Rabb The Role for T Cell Repertoire/Antigen-Specific Interactions in Experimental Kidney Ischemia Reperfusion Injury J. Immunol., July 15, 2009; 183(2): 984 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Relland, M. K. Mishra, D. Haribhai, B. Edwards, J. Ziegelbauer, and C. B. Williams Affinity-Based Selection of Regulatory T Cells Occurs Independent of Agonist-Mediated Induction of Foxp3 Expression J. Immunol., February 1, 2009; 182(3): 1341 - 1350. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Schmidt, C. J. Wang, G. A. Ryan, L. E. Clough, O. S. Qureshi, M. Goodall, A. K. Abbas, A. H. Sharpe, D. M. Sansom, and L. S. K. Walker CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity J. Immunol., January 1, 2009; 182(1): 274 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Lathrop, N. A. Santacruz, D. Pham, J. Luo, and C.-S. Hsieh Antigen-specific peripheral shaping of the natural regulatory T cell population J. Exp. Med., December 22, 2008; 205(13): 3105 - 3117. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kovar, J. Tomala, H. Chmelova, L. Kovar, T. Mrkvan, R. Joskova, Z. Zakostelska, T. Etrych, J. Strohalm, K. Ulbrich, et al. Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8+ T-Cell-Mediated BCL1-Specific Resistance in Mice Cured by Targeted Polymer-Bound Doxorubicin Cancer Res., December 1, 2008; 68(23): 9875 - 9883. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Simone, A. Zicca, and D. Saverino The frequency of regulatory CD3+CD8+CD28-CD25+ T lymphocytes in human peripheral blood increases with age J. Leukoc. Biol., December 1, 2008; 84(6): 1454 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Abe, S. Ueha, J. Suzuki, Y. Tokano, K. Matsushima, and S. Ishikawa Increased Foxp3+ CD4+ Regulatory T Cells with Intact Suppressive Activity but Altered Cellular Localization in Murine Lupus Am. J. Pathol., December 1, 2008; 173(6): 1682 - 1692. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sharma, A. C.-Y. Ju, J. T. Kung, S. M. Fu, and S.-T. Ju Rapid and Selective Expansion of Nonclonotypic T Cells in Regulatory T Cell-Deficient, Foreign Antigen-Specific TCR-Transgenic Scurfy Mice: Antigen-Dependent Expansion and TCR Analysis J. Immunol., November 15, 2008; 181(10): 6934 - 6941. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mazzucchelli, J. A. Hixon, R. Spolski, X. Chen, W. Q. Li, V. L. Hall, J. Willette-Brown, A. A. Hurwitz, W. J. Leonard, and S. K. Durum Development of regulatory T cells requires IL-7R{alpha} stimulation by IL-7 or TSLP Blood, October 15, 2008; 112(8): 3283 - 3292. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Y. Wuest, J. Willette-Brown, S. K. Durum, and A. A. Hurwitz The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells J. Leukoc. Biol., October 1, 2008; 84(4): 973 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Laronne-Bar-On, D. Zipori, and N. Haran-Ghera Increased Regulatory versus Effector T Cell Development Is Associated with Thymus Atrophy in Mouse Models of Multiple Myeloma J. Immunol., September 1, 2008; 181(5): 3714 - 3724. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zheng, C. N. Manzotti, F. Burke, L. Dussably, O. Qureshi, L. S. K. Walker, and D. M. Sansom Acquisition of Suppressive Function by Activated Human CD4+CD25- T Cells Is Associated with the Expression of CTLA-4 Not FoxP3 J. Immunol., August 1, 2008; 181(3): 1683 - 1691. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Onishi, Z. Fehervari, T. Yamaguchi, and S. Sakaguchi Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation PNAS, July 22, 2008; 105(29): 10113 - 10118. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Yu, C. L. Haymaker, R. D. Divekar, J. S. Ellis, J. Hardaway, R. Jain, D. M. Tartar, C. M. Hoeman, J. A. Cascio, A. Ostermeier, et al. Fetal Exposure to High-Avidity TCR Ligand Enhances Expansion of Peripheral T Regulatory Cells J. Immunol., July 1, 2008; 181(1): 73 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mittal, N. A. Marshall, L. Duncan, D. J. Culligan, R. N. Barker, and M. A. Vickers Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma Blood, June 1, 2008; 111(11): 5359 - 5370. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kang, S. J. Huddleston, J. M. Fraser, and A. Khoruts De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR J. Leukoc. Biol., May 1, 2008; 83(5): 1230 - 1239. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. C. Lutsiak, Y. Tagaya, A. J. Adams, J. Schlom, and H. Sabzevari Tumor-Induced Impairment of TCR Signaling Results in Compromised Functionality of Tumor-Infiltrating Regulatory T Cells J. Immunol., May 1, 2008; 180(9): 5871 - 5881. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Bonelli, K von Dalwigk, A Savitskaya, J S Smolen, and C Scheinecker Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis Ann Rheum Dis, May 1, 2008; 67(5): 664 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Tonomura, K. Habiro, A. Shimizu, M. Sykes, and Y.-G. Yang Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model Blood, April 15, 2008; 111(8): 4293 - 4296. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Du, C. Huang, B. Zhou, and S. F. Ziegler Isoform-Specific Inhibition of ROR{alpha}-Mediated Transcriptional Activation by Human FOXP3 J. Immunol., April 1, 2008; 180(7): 4785 - 4792. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Santner-Nanan, N. Seddiki, E. Zhu, V. Quent, A. Kelleher, B. F. de St Groth, and R. Nanan Accelerated age-dependent transition of human regulatory T cells to effector memory phenotype Int. Immunol., March 1, 2008; 20(3): 375 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Barron, B. Knoechel, J. Lohr, and A. K. Abbas Cutting Edge: Contributions of Apoptosis and Anergy to Systemic T Cell Tolerance J. Immunol., March 1, 2008; 180(5): 2762 - 2766. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Larkin III, A. L. Rankin, C. C. Picca, M. P. Riley, S. A. Jenks, A. J. Sant, and A. J. Caton CD4+CD25+ Regulatory T Cell Repertoire Formation Shaped by Differential Presentation of Peptides from a Self-Antigen J. Immunol., February 15, 2008; 180(4): 2149 - 2157. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Dal Secco, A. Riccioli, F. Padula, E. Ziparo, and A. Filippini Mouse Sertoli Cells Display Phenotypical and Functional Traits of Antigen-Presenting Cells in Response to Interferon Gamma Biol Reprod, February 1, 2008; 78(2): 234 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Spence and E. A. Green Foxp3+ regulatory T cells promiscuously accept thymic signals critical for their development PNAS, January 22, 2008; 105(3): 973 - 978. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, E. J. Gowans, C. Chougnet, M. Plebanski, and U. Dittmer Natural Regulatory T Cells and Persistent Viral Infection J. Virol., January 1, 2008; 82(1): 21 - 30. [Full Text] [PDF] |
||||
![]() |
C. Siewert, U. Lauer, S. Cording, T. Bopp, E. Schmitt, A. Hamann, and J. Huehn Experience-Driven Development: Effector/Memory-Like {alpha}E+Foxp3+ Regulatory T Cells Originate from Both Naive T Cells and Naturally Occurring Naive-Like Regulatory T Cells J. Immunol., January 1, 2008; 180(1): 146 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Saitoh, N. Abiru, M. Nakahara, and Y. Nagayama CD8+CD122+ T Cells, a Newly Identified Regulatory T Subset, Negatively Regulate Graves' Hyperthyroidism in a Murine Model Endocrinology, December 1, 2007; 148(12): 6040 - 6046. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ribot, G. Enault, S. Pilipenko, A. Huchenq, M. Calise, D. Hudrisier, P. Romagnoli, and J. P. M. van Meerwijk Shaping of the Autoreactive Regulatory T Cell Repertoire by Thymic Cortical Positive Selection J. Immunol., November 15, 2007; 179(10): 6741 - 6748. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sutmuller, A. Garritsen, and G. J Adema Regulatory T cells and toll-like receptors: regulating the regulators Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii91 - iii95. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Joetham, K. Takeda, N. Miyahara, S. Matsubara, H. Ohnishi, T. Koya, A. Dakhama, and E. W. Gelfand Activation of naturally occurring lung CD4+CD25+ regulatory T cells requires CD8 and MHC I interaction PNAS, September 18, 2007; 104(38): 15057 - 15062. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Kang, H. W. Lim, O. M. Andrisani, H. E. Broxmeyer, and C. H. Kim Vitamin A Metabolites Induce Gut-Homing FoxP3+ Regulatory T Cells J. Immunol., September 15, 2007; 179(6): 3724 - 3733. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Kapp, K. Honjo, L. M. Kapp, K. Goldsmith, and R. P. Bucy Antigen, in the Presence of TGF-beta, Induces Up-Regulation of FoxP3gfp+ in CD4+ TCR Transgenic T Cells That Mediate Linked Suppression of CD8+ T Cell Responses J. Immunol., August 15, 2007; 179(4): 2105 - 2114. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. J. van der Marel, J. N. Samsom, M. Greuter, L. A. van Berkel, T. O'Toole, G. Kraal, and R. E. Mebius Blockade of IDO Inhibits Nasal Tolerance Induction J. Immunol., July 15, 2007; 179(2): 894 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nishihara, H. Ogura, N. Ueda, M. Tsuruoka, C. Kitabayashi, F. Tsuji, H. Aono, K. Ishihara, E. Huseby, U. A. K. Betz, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state Int. Immunol., June 1, 2007; 19(6): 695 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Stephens, J. Andersson, and E. M. Shevach Distinct Subsets of FoxP3+ Regulatory T Cells Participate in the Control of Immune Responses J. Immunol., June 1, 2007; 178(11): 6901 - 6911. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson Rapamycin-Conditioned Dendritic Cells Are Poor Stimulators of Allogeneic CD4+ T Cells, but Enrich for Antigen-Specific Foxp3+ T Regulatory Cells and Promote Organ Transplant Tolerance J. Immunol., June 1, 2007; 178(11): 7018 - 7031. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Adler, S. Kubsch, E. Graulich, S. Ludwig, J. Knop, and K. Steinbrink Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells Blood, May 15, 2007; 109(10): 4351 - 4359. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Pereira, F. Villinger, N. Onlamoon, P. Bryan, A. Cardona, K. Pattanapanysat, K. Mori, S. Hagen, L. Picker, and A. A. Ansari Simian Immunodeficiency Virus (SIV) Infection Influences the Level and Function of Regulatory T Cells in SIV-Infected Rhesus Macaques but Not SIV-Infected Sooty Mangabeys J. Virol., May 1, 2007; 81(9): 4445 - 4456. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Peterson, D. T. Nardelli, T. F. Warner, S. M. Callister, J. R. Torrealba, and R. F. Schell Anti-p19 Antibody Treatment Exacerbates Lyme Arthritis and Enhances Borreliacidal Activity Clin. Vaccine Immunol., May 1, 2007; 14(5): 510 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhan, D. Bourges, J. A. Dromey, L. C. Harrison, and A. M. Lew The origin of thymic CD4+CD25+ regulatory T cells and their co-stimulatory requirements are determined after elimination of recirculating peripheral CD4+ cells Int. Immunol., April 1, 2007; 19(4): 455 - 463. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Hilchey, A. De, L. M. Rimsza, R. B. Bankert, and S. H. Bernstein Follicular Lymphoma Intratumoral CD4+CD25+GITR+ Regulatory T Cells Potently Suppress CD3/CD28-Costimulated Autologous and Allogeneic CD8+CD25- and CD4+CD25- T Cells J. Immunol., April 1, 2007; 178(7): 4051 - 4061. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Turner, P. A. Cohen, and O. J. Finn Lack of Effective MUC1 Tumor Antigen-Specific Immunity in MUC1-Transgenic Mice Results from a Th/T Regulatory Cell Imbalance That Can Be Corrected by Adoptive Transfer of Wild-Type Th Cells J. Immunol., March 1, 2007; 178(5): 2787 - 2793. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Mannie, B. A. Clayson, E. J. Buskirk, J. L. DeVine, J. J. Hernandez, and D. J. Abbott IL-2/Neuroantigen Fusion Proteins as Antigen-Specific Tolerogens in Experimental Autoimmune Encephalomyelitis (EAE): Correlation of T Cell-Mediated Antigen Presentation and Tolerance Induction J. Immunol., March 1, 2007; 178(5): 2835 - 2843. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Liu, L. Y. Wong, T. Jang, A. H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B. A. Teicher, and C. Lee Tumor Evasion of the Immune System by Converting CD4+CD25- T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-beta J. Immunol., March 1, 2007; 178(5): 2883 - 2892. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Callaghan, F. J. Rouhani, M. C. Negus, A. J. Curry, E. M. Bolton, J. A. Bradley, and G. J. Pettigrew Abrogation of Antibody-Mediated Allograft Rejection by Regulatory CD4 T Cells with Indirect Allospecificity J. Immunol., February 15, 2007; 178(4): 2221 - 2228. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Peluso, M. C. Fantini, D. Fina, R. Caruso, M. Boirivant, T. T. MacDonald, F. Pallone, and G. Monteleone IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes J. Immunol., January 15, 2007; 178(2): 732 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Venturi, R. M. Conway, D. A. Steeber, and T. F. Tedder CD25+CD4+ Regulatory T Cell Migration Requires L-Selectin Expression: L-Selectin Transcriptional Regulation Balances Constitutive Receptor Turnover J. Immunol., January 1, 2007; 178(1): 291 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lee, S. G. Kang, and C. H. Kim FoxP3+ T Cells Undergo Conventional First Switch to Lymphoid Tissue Homing Receptors in Thymus but Accelerated Second Switch to Nonlymphoid Tissue Homing Receptors in Secondary Lymphoid Tissues J. Immunol., January 1, 2007; 178(1): 301 - 311. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Keino, M Takeuchi, Y Usui, T Hattori, N Yamakawa, T Kezuka, J-I Sakai, and M Usui Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis Br J Ophthalmol, January 1, 2007; 91(1): 105 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tuovinen, J. T. Salminen, and T. P. Arstila Most human thymic and peripheral-blood CD4+CD25+ regulatory T cells express 2 T-cell receptors Blood, December 15, 2006; 108(13): 4063 - 4070. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-B. Sun, S. Raghavan, A. Sjoling, S. Lundin, and J. Holmgren Oral Tolerance Induction with Antigen Conjugated to Cholera Toxin B Subunit Generates Both Foxp3+CD25+ and Foxp3-CD25- CD4+ Regulatory T Cells J. Immunol., December 1, 2006; 177(11): 7634 - 7644. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Hillebrands, B. Whalen, J. T. J. Visser, J. Koning, K. D. Bishop, J. Leif, J. Rozing, J. P. Mordes, D. L. Greiner, and A. A. Rossini A Regulatory CD4+ T Cell Subset in the BB Rat Model of Autoimmune Diabetes Expresses Neither CD25 Nor Foxp3 J. Immunol., December 1, 2006; 177(11): 7820 - 7832. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Marodon, S. Fisson, B. Levacher, M. Fabre, B. L. Salomon, and D. Klatzmann Induction of antigen-specific tolerance by intrathymic injection of lentiviral vectors Blood, November 1, 2006; 108(9): 2972 - 2978. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tischner, A. Weishaupt, J. v. d. Brandt, N. Muller, N. Beyersdorf, C. W. Ip, K. V. Toyka, T. Hunig, R. Gold, T. Kerkau, et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis Brain, October 1, 2006; 129(10): 2635 - 2647. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Lawson, A. K. Brown, V. Bejarano, S. H. Douglas, C. H. Burgoyne, A. S. Greenstein, A. W. Boylston, P. Emery, F. Ponchel, and J. D. Isaacs Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood Rheumatology, October 1, 2006; 45(10): 1210 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Ford, Z.-X. Zhang, W. Chen, and L. Zhang Double-Negative T Regulatory Cells Can Develop Outside the Thymus and Do Not Mature from CD8+ T Cell Precursors. J. Immunol., September 1, 2006; 177(5): 2803 - 2809. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Nardelli, T. F. Warner, S. M. Callister, and R. F. Schell Anti-CD25 Antibody Treatment of Mice Vaccinated and Challenged with Borrelia spp. Does Not Exacerbate Arthritis but Inhibits Borreliacidal Antibody Production. Clin. Vaccine Immunol., August 1, 2006; 13(8): 884 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Scalapino, Q. Tang, J. A. Bluestone, M. L. Bonyhadi, and D. I. Daikh Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells J. Immunol., August 1, 2006; 177(3): 1451 - 1459. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Lim, H. E. Broxmeyer, and C. H. Kim Regulation of Trafficking Receptor Expression in Human Forkhead Box P3+ Regulatory T Cells J. Immunol., July 15, 2006; 177(2): 840 - 851. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Valmori, V. Tosello, N. E. Souleimanian, E. Godefroy, L. Scotto, Y. Wang, and M. Ayyoub Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells J. Immunol., July 15, 2006; 177(2): 944 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lan, N. Tonomura, A. Shimizu, S. Wang, and Y.-G. Yang Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation Blood, July 15, 2006; 108(2): 487 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y.-S. Tsang, N. O. S. Camara, E. Eren, H. Schneider, C. Rudd, G. Lombardi, and R. Lechler Altered proximal T cell receptor (TCR) signaling in human CD4+CD25+ regulatory T cells J. Leukoc. Biol., July 1, 2006; 80(1): 145 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Alard, J. N. Manirarora, S. A. Parnell, J. L. Hudkins, S. L. Clark, and M. M. Kosiewicz Deficiency in NOD Antigen-Presenting Cell Function May Be Responsible for Suboptimal CD4+CD25+ T-Cell-Mediated Regulation and Type 1 Diabetes Development in NOD Mice. Diabetes, July 1, 2006; 55(7): 2098 - 2105. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wing, Z. Fehervari, and S. Sakaguchi Emerging possibilities in the development and function of regulatory T cells Int. Immunol., July 1, 2006; 18(7): 991 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shimoda, F. Mmanywa, S. K. Joshi, T. Li, K. Miyake, J. Pihkala, J. A. Abbas, and P. A. Koni Conditional Ablation of MHC-II Suggests an Indirect Role for MHC-II in Regulatory CD4 T Cell Maintenance. J. Immunol., June 1, 2006; 176(11): 6503 - 6511. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nishioka, J. Shimizu, R. Iida, S. Yamazaki, and S. Sakaguchi CD4+CD25+Foxp3+ T Cells and CD4+CD25-Foxp3+ T Cells in Aged Mice. J. Immunol., June 1, 2006; 176(11): 6586 - 6593. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Vanasek, S. L. Nandiwada, M. K. Jenkins, and D. L. Mueller CD25+Foxp3+ Regulatory T Cells Facilitate CD4+ T Cell Clonal Anergy Induction during the Recovery from Lymphopenia J. Immunol., May 15, 2006; 176(10): 5880 - 5889. [Abstract] [Full Text] [PDF] |
||||
![]() |
M C Fantini, C Becker, I Tubbe, A Nikolaev, H A Lehr, P Galle, and M F Neurath Transforming growth factor {beta} induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis Gut, May 1, 2006; 55(5): 671 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Nicolson, E. J. O'Neill, A. Sundstedt, H. B. Streeter, S. Minaee, and D. C. Wraith Antigen-Induced IL-10+ Regulatory T Cells Are Independent of CD25+ Regulatory Cells for Their Growth, Differentiation, and Function J. Immunol., May 1, 2006; 176(9): 5329 - 5337. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Z. Yang, A. J. Novak, M. J. Stenson, T. E. Witzig, and S. M. Ansell Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma Blood, May 1, 2006; 107(9): 3639 - 3646. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Gavin, T. R. Torgerson, E. Houston, P. deRoos, W. Y. Ho, A. Stray-Pedersen, E. L. Ocheltree, P. D. Greenberg, H. D. Ochs, and A. Y. Rudensky Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development PNAS, April 25, 2006; 103(17): 6659 - 6664. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ono, J. Shimizu, Y. Miyachi, and S. Sakaguchi Control of Autoimmune Myocarditis and Multiorgan Inflammation by Glucocorticoid-Induced TNF Receptor Family-Related Proteinhigh, Foxp3-Expressing CD25+ and CD25- Regulatory T Cells. J. Immunol., April 15, 2006; 176(8): 4748 - 4756. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Keino, M. Takeuchi, T. Kezuka, T. Hattori, M. Usui, O. Taguchi, J. W. Streilein, and J. Stein-Streilein Induction of Eye-Derived Tolerance Does Not Depend on Naturally Occurring CD4+CD25+ T Regulatory Cells. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1047 - 1055. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Koonpaew, S. Shen, L. Flowers, and W. Zhang LAT-mediated signaling in CD4+CD25+ regulatory T cell development J. Exp. Med., January 23, 2006; 203(1): 119 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sanchez-Fueyo, S. Sandner, A. Habicht, C. Mariat, J. Kenny, N. Degauque, X. X. Zheng, T. B. Strom, L. A. Turka, and M. H. Sayegh Specificity of CD4+CD25+ Regulatory T Cell Function in Alloimmunity J. Immunol., January 1, 2006; 176(1): 329 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Endharti, M. Rifa' I, Z. Shi, Y. Fukuoka, Y. Nakahara, Y. Kawamoto, K. Takeda, K.-i. Isobe, and H. Suzuki Cutting Edge: CD8+CD122+ Regulatory T Cells Produce IL-10 to Suppress IFN-{gamma} Production and Proliferation of CD8+ T Cells J. Immunol., December 1, 2005; 175(11): 7093 - 7097. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. DiPaolo, D. D. Glass, K. E. Bijwaard, and E. M. Shevach CD4+CD25+ T Cells Prevent the Development of Organ-Specific Autoimmune Disease by Inhibiting the Differentiation of Autoreactive Effector T Cells J. Immunol., December 1, 2005; 175(11): 7135 - 7142. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wolf, A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius, and C. Marth The Expression of the Regulatory T Cell-Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer Clin. Cancer Res., December 1, 2005; 11(23): 8326 - 8331. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Durinovic-Bello, E. Jelinek, M. Schlosser, T. Eiermann, B. O. Boehm, W. Karges, L. Marchand, and C. Polychronakos Class III Alleles at the Insulin VNTR Polymorphism Are Associated With Regulatory T-Cell Responses to Proinsulin Epitopes in HLA-DR4, DQ8 Individuals Diabetes, December 1, 2005; 54(suppl_2): S18 - S24. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Romagnoli, D. Hudrisier, and J. P. M. van Meerwijk Molecular Signature of Recent Thymic Selection Events on Effector and Regulatory CD4+ T Lymphocytes J. Immunol., November 1, 2005; 175(9): 5751 - 5758. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Skapenko, J. R. Kalden, P. E. Lipsky, and H. Schulze-Koops The IL-4 Receptor {alpha}-Chain-Binding Cytokines, IL-4 and IL-13, Induce Forkhead Box P3-Expressing CD25+CD4+ Regulatory T Cells from CD25-CD4+ Precursors J. Immunol., November 1, 2005; 175(9): 6107 - 6116. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Siegmund, M. Feuerer, C. Siewert, S. Ghani, U. Haubold, A. Dankof, V. Krenn, M. P. Schon, A. Scheffold, J. B. Lowe, et al. Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo Blood, November 1, 2005; 106(9): 3097 - 3104. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Fontenot, J. L. Dooley, A. G. Farr, and A. Y. Rudensky Developmental regulation of Foxp3 expression during ontogeny J. Exp. Med., October 3, 2005; 202(7): 901 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bienvenu, B. Martin, C. Auffray, C. Cordier, C. Becourt, and B. Lucas Peripheral CD8+CD25+ T Lymphocytes from MHC Class II-Deficient Mice Exhibit Regulatory Activity J. Immunol., July 1, 2005; 175(1): 246 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Ruprecht, M. Gattorno, F. Ferlito, A. Gregorio, A. Martini, A. Lanzavecchia, and F. Sallusto Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia J. Exp. Med., June 6, 2005; 201(11): 1793 - 1803. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |